Reflection paper on the dissolution specification for ...
Reflection paper on the dissolution specification for generic solid oral immediate release products with systemic action EMA/CHMP/CVMP/QWP/336031/2017 Page 2/10
Download Reflection paper on the dissolution specification for ...
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
A Brief Review of the FDA Dissolution Methods …
www.dissolutiontech.com6 T TINTRODUCTION he dissolution profile test is one of the most useful methods used in different stages of the drug product lifecycle: pharmaceutical development,
In Vitro Release Testing of Semi-Solid Dosage Forms
www.dissolutiontech.com52 I BACKGROUND n vitro release testing (IVRT) is used to monitor the release and diffusion of drug products from semisolid dosage forms (1–11) and has long been considered a valuable tool in formulation development.
INDUSTRIAL PROCESS VALIDATION OF SOLID …
www.globalresearchonline.netVolume 4, Issue 2, September – October 2010; Article 025 ISSN 0976 – 044X
MEDICINES CONTROL COUNCIL - mccza.com
www.mccza.comRegistration of Medicines Pharmaceutical & Analytical 2.02 PA Jun11 v6 showing changes.doc Page June 2011 3 of 27 Back to ToC 1 INTRODUCTION The requirements for pharmaceutical and analytical information are divided into ten parts in the
Comparison of dissolution profile of extended …
www.scielo.brComparison of dissolution profile of extended-release oral dosage forms – Two one-sided equivalence test 369 dissolution test of extended-release dosage forms as a
2.9.3. DISSOLUTION TEST FOR SOLID DOSAGE …
www.uspbpep.com2.9.3. Dissolution test for solid dosage forms EUROPEAN PHARMACOPOEIA 5.0 For the basket apparatus, place the preparation in a …
2.9.3. DISSOLUTION TEST FOR SOLID DOSAGE …
www.uspbpep.com2.9.3. Dissolution test for solid dosage forms EUROPEAN PHARMACOPOEIA 6.0 beaker with a capacity of at least 4 litres filled with water maintained at 36-37 °C, unless otherwise prescribed.